b

Search documents
X @Bloomberg
Bloomberg· 2025-07-23 07:16
India’s overnight rates have risen above the central bank’s key policy rate, driven by monthly tax outflows, which could result in weakened participation at the central bank’s next liquidity absorption auction https://t.co/DJrGLB3ZdA ...
免费领取!2025年全球锂电产业链分布图
鑫椤锂电· 2025-07-23 07:04
转发本文到朋友圈 ,添加小编免费领取, 13248122922 (微信同)。 分布图内容 分布图尺寸:1.5米X1米 从覆盖行业角度,本分布图细致入微地描绘了全球锂电产业从原材料、四大主材、电池制造到终端 应用的全链条生态。从覆盖地域角度,本分布图包含中国、北美、欧洲、日韩东南亚四大锂电产业 主要聚集区。 分布图领取资格 关注公众号,点击公众号主页右上角" ··· ",设置星标 "⭐" ,关注 鑫椤固态电池 资讯~ 2025年全球锂电产业链分布图 I C C S I N O 分布图快递详情 正在按照登记顺序,依次派发中...... 分布图领取 ▼ ...
上半年上海地区证券业客户资产达12.65万亿元 同比增23.3%
Xin Hua Cai Jing· 2025-07-23 07:04
新华财经上海7月23日电上海市证券同业公会23日发布2025年上半年上海地区证券经纪业务分支机构经 营简况,上海地区分支机构期末客户资产总额达12.65万亿元,同比上升23.3%。 其中,在从事经纪业务经营的会员数方面,2025年上半年末,上海地区证券经纪业务分支机构共计853 家。含分公司104家,营业部749家,含A类59家,B类250家,C类440家。 A股交易量方面,上半年,上海地区分支机构沪深A股交易量为47.95万亿元,同比上升69.2%,A股交易 量最大一家分支机构为3.78万亿元,共有6家分支机构交易量过万亿元。全国沪深A股交易量为159.2万 亿元,上海地区占比30.12%,较去年上升1.83个百分点。 在收入上,上半年上海地区分支机构营业收入(含佣金收入、利息)为148.44亿元,同比上升47.1%。 其中,营业收入过1000万元的共有356家,占比41%;低于100万元的共有98家,占比11%(营业收入包 含统计期间既往撤销、合并等分支机构数据)。 客户资产方面,上海地区分支机构期末客户资产总额为12.65万亿元,同比上升23.3%,资产总额最大的 分支机构数达到1.25万亿元,占比9. ...
RETRANSMISSION: Cruz Battery Metals Board Approves Strategic Diversification into Crypto Assets
Newsfile· 2025-07-23 07:01
Core Viewpoint - Cruz Battery Metals Corp. has approved a strategic initiative to diversify a portion of its free cash into select crypto assets, aiming to enhance shareholder value and align with emerging global trends [1][2][3]. Group 1: Strategic Initiative - The decision to invest in crypto assets is part of Cruz's commitment to exploring innovative investment avenues while maintaining its core focus on battery metals exploration, particularly lithium and cobalt [2][3]. - This diversification strategy is intended to strengthen the company's balance sheet by gaining exposure to digital assets with long-term growth potential [2][3]. Group 2: Management Commentary - The President of Cruz Battery Metals stated that this strategic step reflects a proactive approach to capital management, presenting an additional opportunity to enhance shareholder value alongside core operations [3]. - The crypto market has seen renewed momentum, and companies in this space have demonstrated strong investor interest, which supports Cruz's decision to diversify [3]. Group 3: Core Operations - Cruz's primary business remains focused on advancing its U.S.-based battery metals projects, including the 4,938-acre Solar Lithium Project, Clayton Valley lithium brine assets, and Idaho Cobalt Belt Project [3][4]. - The company will continue to evaluate all investment opportunities prudently, with the goal of sustainable, long-term growth [3].
X @BitMart
BitMart· 2025-07-23 07:00
#BitMart Daily Market Hot Information - July 23, 2025 🚀📊Crypto Market Cap: $3.95 Trillion (+2.17%)📈BTC ETF Net Flow: -$67.9M📉ETH ETF Net Flow: +$534M🤑Fear & Greed Index: 70 (Greed)🔥 Top Gainers: #BALANCE (+1800%), $DOG (+255.87%), #MEMECOIN (+219.54%) & more!📢 Stay ahead with the latest trends! ...
信达生物(01801):二代IO重磅潜力凸显,全球化Biopharma扬帆起航报
Guotou Securities· 2025-07-23 06:56
2025 年 07 月 23 日 信达生物(01801.HK) 二 代 IO 重 磅 潜 力 凸 显 , 全 球 化 未来核心关注点:多个驱动公司从中国 Biopharma 向全球化 Biopharma 转型的关键要素正逐步兑现。公司正处于从中国 Biopharma 向全球化 Biopharma 转型的关键阶段,其中:PD-1/IL- 2α双抗 IBI363 的海外授权有望奠定转型基础,而 2027 年产品 销售收入 200 亿元指引的完成有望巩固国内市场基本盘,此外新 一代 IO+ADC 布局、自免&代谢领域早研 FIC 产品未来有望成为下 一个海外市场突破点。 投资建议:考虑到已上市产品及在研产品的放量趋势,我们预 计公司 2025-2027 年营业收入分别为 119.0 亿元、157.5 亿元、 204.0 亿元,净利润分别为 7.0 亿元、18.4 亿元、29.2 亿元。我 们采取 DCF 估值方法得到的公司价值约为 1687 亿元,对应 1846 本报告版权属于国投证券股份有限公司,各项声明请参见报告尾页。 1 公司深度分析 | | 证券研究报告 | | | --- | --- | --- | | ...
X @wale.moca 🐳
wale.moca 🐳· 2025-07-23 06:54
Onboarding Web2 audiences to crypto is still a challenge, but both Web3-native brands and big players from Web2 have made good process here since the last cycle imo.I took a closer look today at how OneFootball is currently onboarding its users and the process is pretty straightforward.TLDR is OneFootball plans bring their tens of million fans on-chain along with their partners Base, FIFA Rivals and Animoca Brands.This has a few different elements:I claimed my wale .football ID and that was pretty easy, mor ...
Samsung Biologics reports second quarter 2025 financial results
Prnewswire· 2025-07-23 06:54
Core Insights - Samsung Biologics reported strong financial results for Q2 2025, with consolidated revenue of KRW 1,289.9 billion and operating profit of KRW 475.6 billion, reflecting a year-over-year increase in revenue of 11.5% and operating profit of 9.5% [3][4][9] Financial Performance - The standalone revenue for Samsung Biologics in Q2 2025 was KRW 1,014.2 billion, with an operating profit of KRW 477.0 billion, driven by full utilization of Plants 1 through 3 and the ramp-up of Plant 4 [3][4] - In the first half of 2025, standalone revenue exceeded KRW 2 trillion, with sales contract volume reaching USD 2.4 billion, bringing the cumulative value to USD 18.7 billion [4] Business Developments - The company has fully operationalized Plant 5, adding 180 kL of capacity to enhance manufacturing capabilities and meet client needs [5] - Samsung Biologics launched Samsung Organoids, a new research service utilizing patient-derived organoids for drug discovery, enabling precision screening and multi-modal insights [6] - Plans to spin off Samsung Bioepis were announced, allowing the company to focus on its core CDMO capabilities and enhance customer satisfaction [7] Sustainability Initiatives - Samsung Biologics released its 2025 ESG report, highlighting a 24% reduction in greenhouse gas emissions in 2024 and an increase in renewable energy use to 29% of total electricity consumption [8] - The company signed a solar Power Purchase Agreement to support its energy transition and is involved in initiatives to decarbonize healthcare supply chains [10] Industry Position - Samsung Biologics operates with a combined biomanufacturing capacity of 784 kL across five plants, offering end-to-end integrated services from late discovery to commercial manufacturing [11] - The company leverages advanced technologies to advance diverse modalities, including multispecific antibodies and mRNA therapeutics, positioning itself as a leader in the CDMO sector [11][12]
X @The Economist
The Economist· 2025-07-23 06:40
Picture the British Medical Association, the main doctors’ union, and you may imagine a professional body of tweed-wearers. It is more like a giant version of Extinction Rebellion https://t.co/wSB44LEGeI ...
X @Decrypt
Decrypt· 2025-07-23 06:37
Japan's Kitabo Joins Growing List of Asian Firms Turning to Bitcoin Amid Financial Strain► https://t.co/z2wzpeJBpf https://t.co/z2wzpeJBpf ...